Last reviewed · How we verify
NCT05939596
A Phase I Clinical Trial to Evaluate the Safety, Tolerability, and Immunogenicity of SARS-CoV-2 Bivalent mRNA Vaccine (LVRNA021)
Phase 1 trial testing SARS-CoV-2 Bivalent mRNA Vaccine in SARS-CoV-2 in 60 participants. Status unknown.
28 September 2023
Quick facts
| Lead sponsor | AIM Vaccine Co., Ltd. |
|---|---|
| Phase | Phase 1 |
| Status | Status unknown |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | quadruple |
| Primary purpose | prevention |
| Enrollment | 60 |
| Start date | 10 August 2023 |
| Primary completion | 28 September 2023 |
| Estimated completion | 25 August 2024 |
| Sites | 1 location across China |
Drugs / interventions tested
- SARS-CoV-2 Bivalent mRNA Vaccine — full drug profile →
- Saline
Conditions studied
- SARS-CoV-2 — all drugs for SARS-CoV-2 →
Sponsor
AIM Vaccine Co., Ltd. — full company profile →
Who can join
18 and older, any sex, with SARS-CoV-2. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This trial is a phase I clinical trial of a SARS-CoV-2 Bivalent mRNA Vaccine (LVRNA021). The trial used a randomized, blinded, placebo-controlled design to evaluate the safety, tolerability, and preliminary immunogenicity of the trial vaccine in participants Aged 18 Years and Older who had received SARS-CoV-2 Vaccine.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT05939596
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of SARS-CoV-2 Bivalent mRNA Vaccine
Trials testing the same drug.
- NCT05939648 — A Phase II Clinical Trial to Evaluate the Immunogenicity and Safety of SARS-CoV-2 Bivalent mRNA Vaccine (LVRNA021) · Phase 2 · unknown
Other recruiting trials for SARS-CoV-2
Currently open trials in the same condition.
- NCT07266558 — A Study to Evaluate the Efficacy and Safety of mRNA-1283 and mRNA-1273 in Participants 50 to 64 Years of Age Without Hig · Phase 4 · recruiting
- NCT06684379 — Study on Safety and Efficacy of Two Doses of PRS CK STORM in the Modulation of the Cytokine Storm for the Treatment of A · Phase 1, PHASE2 · recruiting
- NCT06585241 — A Study to Investigate the Immunogenicity and Safety of mRNA COVID-19 Variant-containing Vaccine Formulations · Phase 4 · recruiting
- NCT05876377 — Use and Effectiveness of COVID-19 Vaccines Using State Vaccine Registries and Insurance Claims Data · active not recruiting
- NCT05799651 — Safety and Immunogenicity of Glycovax-002 Vaccine in Healthy Adults · Phase 1 · active not recruiting
Other AIM Vaccine Co., Ltd. trials
Trials by the same sponsor.
- NCT05939648 — A Phase II Clinical Trial to Evaluate the Immunogenicity and Safety of SARS-CoV-2 Bivalent mRNA Vaccine (LVRNA021) · Phase 2 · unknown
- NCT05352867 — Clinical Trial of SARS-CoV-2 mRNA Vaccine in Chinese People · Phase 2 · completed
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT05939596 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by AIM Vaccine Co., Ltd.
- Last refreshed: 22 November 2023
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05939596.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing